Kodiak Sciences Inc (KOD) USD0.0001

Sell:$3.90Buy:$4.33$0.11 (2.63%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$3.90
Buy:$4.33
Change:$0.11 (2.63%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$3.90
Buy:$4.33
Change:$0.11 (2.63%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Key people

Victor Perlroth
Chairman of the Board, Chief Executive Officer, Co-Founder
John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Robert A. Profusek
Lead Independent Director
Felix J. Baker
Independent Director
Charles A. Bancroft
Independent Director
Bassil I. Dahiyat
Independent Director
Richard S. Levy
Independent Director
Click to see more

Key facts

  • EPIC
    KOD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US50015M1099
  • Market cap
    $210.53m
  • Employees
    109
  • Shares in issue
    52.98m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.